Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HuaSin In-licenses China Rights to HPV Diagnostic from Spain's Genomica

publication date: Feb 20, 2019

HuaSin Science of Guangzhou obtained exclusive China rights to a test that offers early detection of HPV, a precursor to cervical cancer, from Genomica of Madrid. HuaSin, which will produce the test under its own DiBao label, has started the China registration process and expects a China launch in 2021. HuaSin distributes clinical laboratory instruments, medical devices and reagents, manufactures in vitro diagnostics products and provides thirty-party clinical laboratory services. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital